{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"20","upperLimit":"58","value":"39"},{"groupId":"OG001","lowerLimit":"28","upperLimit":"78","value":"57"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"23"},{"groupId":"OG001","value":"14"}],"units":"Participants"}],"description":"Determine the progression-free survival rate at 6 months after study entry in each cohort. This is the percentage of subjects that both have not had disease progression and are alive 6 months after study entry. Progression is defined by RECIST v1.1 criteria and is defined as an increase of at least 20% in the sum of the largest diameters of target lesions and/or the appearance of new lesions.","dispersionType":"95% Confidence Interval","groups":[{"description":"This cohort will enroll patients with mesothelioma, uveal melanoma, renal cell carcinoma (clear cell type), and cholangiocarcinoma.\n\nNiraparib: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.","id":"OG000","title":"Cohort A"},{"description":"This cohort will enroll patients whose tumors have a known DNA damage response mutation in any of the following genes: ARID1A, ATM, ATR, BACH1 (BRIP1), BAP1, BARD1, BLM, CHEK1, CHEK2, CDK2, CDK4, ERCC, FAM175A, FEN1, IDH1, IDH2, MRE11A, NBN (NBS1), PALB2, POLD1, PRKDC (DNA-PK) PTEN, RAD50, RAD51, RAD52, RAD54, RPA1, SLX4, WRN, or XRCC. This cohort is open to patients with any type of malignancy (except prostate).\n\nNiraparib: Patients will take 300 mg of niraparib orally once daily each day of a 28 day cycle.","id":"OG001","title":"Cohort B"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"6 months","title":"Progression-Free Survival Rate at 6 Months","type":"SECONDARY","unitOfMeasure":"percentage of subjects"}